Detalhe da pesquisa
1.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
2.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica
; 103(5): 874-879, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419429
3.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica
; 103(9): 1511-1517, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880613
4.
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Clin Cancer Res
; 28(18): 3958-3964, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35852793
5.
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Clin Cancer Res
; 26(14): 3589-3596, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198151
6.
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Clin Cancer Res
; 25(14): 4264-4270, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004001
7.
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Blood Adv
; 3(10): 1568-1573, 2019 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101647